REGN4461 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
265	脂肪萎縮症	3

265. 脂肪萎縮症

---

臨床試験数 : 112 /  薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05088460 (ClinicalTrials.gov)	February 28, 2022	12/10/2021	A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)	A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients With Familial Partial Lipodystrophy	Familial Partial Lipodystrophy;Metabolic Abnormalities	Drug: REGN4461;Drug: Matching Placebo	Regeneron Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	40	Phase 2	United States;France;Spain;Turkey
2	NCT04710056 (ClinicalTrials.gov)	June 2021	13/1/2021	Expanded Access to REGN4461 for Patients With 1) Generalized Lipodystrophy, 2) Partial Lipodystrophy or 3) Monogenic Obesity Due to LEP or LEPR Loss of Function		Generalized Lipodystrophy;Partial Lipodystrophy;Monogenic Obesity Due to LEP or LEPR Loss of Function	Drug: REGN4461	Regeneron Pharmaceuticals	NULL	Available						NULL
3	NCT04159415 (ClinicalTrials.gov)	January 7, 2020	7/11/2019	Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy	A Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy	Generalized Lipodystrophy	Drug: Placebo;Drug: Low-Dose REGN4461;Drug: High-dose REGN4461	Regeneron Pharmaceuticals	NULL	Active, not recruiting	12 Years	N/A	All	16	Phase 2	United States;Peru;Russian Federation;Turkey